Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Investors can contact the law firm at no cost to learn more about recovering their losses

Quanterix Corporation Investors: Company Investigated by the Portnoy Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Quanterix Corporation Is Being Looked Into For Possible Securities Law Violations And Impacted Investors Are Urged To Reach Out To The Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Quanterix Corporation (QTRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

ATLANTA, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX) complied with federal securities laws. On November 12, 2024, Quanterix announced that the Company needed to restate certain previously issued financial statements due to “an error related to the capitalization of labor and overhead costs applied to prior periods going back to at least 2021, which impacted the valuation of inventory.”  Following this news, the price of the Company's stock dropped.

SHAREHOLDER ALERT: Investigation of Quanterix Corporation (QTRX) Announced by Holzer & Holzer, LLC

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Shareholders To Join An Inquiry Into Quanterix Corporation For Securities Fraud

Quanterix Corporation Is Being Investigated For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Quanterix Corporation (QTRX) and Encourages Investors to Learn More About the Investigation

LOS ANGELES, CA / ACCESSWIRE / December 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants Shareholders To Join An Inquiry Into Quanterix Corporation's Securities Fraud

NEW YORK CITY, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Quanterix Corporation (QTRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

LOS ANGELES, CA / ACCESSWIRE / November 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Quanterix Corporation Is Being Investigated For Possible Securities Law Violations And Impacted Investors Are Invited To Help The Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Quanterix Corporation (QTRX) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Encourages Quanterix Corporation (QTRX) Stockholders to Inquire about Securities Investigation

LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Seeks Shareholder Participation In An Inquiry Into Quanterix Corporation For Securities Fraud

NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Quanterix Corporation (QTRX) And Encourages Stockholders to Reach Out

LOS ANGELES, CA / ACCESSWIRE / November 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Quanterix Corporation Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Help The Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Quanterix Corporation (QTRX) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

Quanterix Corporation Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - QTRX

LOS ANGELES, CA / ACCESSWIRE / November 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Quanterix Corporation For Fraud

NEW YORK CITY, NY / ACCESSWIRE / November 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Quanterix Corporation (QTRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Quanterix Corporation ("Quanterix Corporation") (NASDAQ:QTRX) concerning possible violations of federal securities laws. After the market closed, on November 12, 2024, Quanterix announced that it had "identified an error regarding the capitalization of labor and overhead costs applied to prior periods, dating back to at least 2021," which had affected the valuation of its inventory.

Quanterix Corporation INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Quanterix Corporation (QTRX)

NEW YORK CITY, NY / ACCESSWIRE / November 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Quanterix Corporation (QTRX) and Encourages Stockholders to Learn More About the Investigation

LOS ANGELES, CA / ACCESSWIRE / November 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants Shareholders To Join An Inquiry Into Quanterix Corporation For Defrauding The Public

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all required periodic financial r.

Quanterix Announces Receipt of Expected Notice from Nasdaq

NEW YORK CITY, NY / ACCESSWIRE / November 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

Bronstein, Gewirtz & Grossman, LLC Encourages Quanterix Corporation (QTRX) Investors to Inquire about Securities Investigation

LOS ANGELES, CA / ACCESSWIRE / November 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Quanterix Stock (QTRX)